NCT03954873

Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: Male
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

Infusion of glucagon-like peptide 2 (GLP-2) during euglycaemia, hypoglycaemia and hyperglycaemia and evaluation of the effect on glucagon secretion in healthy subjects.

Detailed description

This is a cross-over, randomized, double-blinded study in which 10 participants will undergo 6 experimental days each. The participants will have their plasma glucose clamped at either euglycaemia (fasting level), hypoglycemia (2,5 mmol/l) or hyperglycemia (10 mmol/l) during infusion of GLP-2 or saline (placebo) The six days will be as follows: * Euglycaemia + Placebo * Euglycaemia + GLP-2 * Hyperglycaemia + Placebo * Hyperglycaemia + GLP-2 * Hypoglycaemia + Placebo * Hypoglycaemia + GLP-2 The primary endpoint will be levels of plasma glucagon. Secondary endpoint will be levels of GLP-1, GLP-2, Insulin/C-peptide, OXM, Amino acids, CCK, Gastrin, norepinephrine, bile acids, FGF-19/FGF-21. Secondary endpoints will also include ultrasound scan of the gallbladder.

Conditions

• Glucose Metabolism Disorders
• Endocrine or Metabolic Disease

Interventions

Type	Name	Description
OTHER	Glucagon-like peptide 2	Human glucagon-like peptide 2
OTHER	Saline	Placebo
OTHER	Glucose	20% (w/v) glucose infusion for regulating plasma glucose
OTHER	Insulin	Actrapid (insulin) for lowering plasma glucose

Timeline

• Start date: 2019-01-31
• Primary completion: 2020-06-01
• Completion: 2020-06-01
• First posted: 2019-05-17
• Last updated: 2020-11-04

Locations

1 site across 1 country: Denmark